Login / Signup

Infectious adverse events in patients with atopic dermatitis treated with baricitinib.

Flaminia AntonelliDalma MalvasoGiacomo CaldarolaClara De SimoneKetty PerisAndrea Chiricozzi
Published in: Immunotherapy (2023)
Baricitinib is a JAK1-2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis in adult patients at doses of 2 and 4 mg daily. The aim of this article is to discuss the safety profile of baricitinib in atopic dermatitis using data from clinical trials and the supporting literature, with a focus on infectious adverse events. An integrated analysis of safety data from eight clinical trials described infections as the most frequent treatment-emergent adverse events, mainly of mild-to-moderate severity, notably upper respiratory tract infections and herpes simplex exacerbations. Real-world data are still limited and will contribute to precisely profile the patients that might benefit from this treatment.
Keyphrases